Maegim한국어

HK이노엔

195940KOSDAQSector: Pharma & Biotech
₩37,800▲ 1.20%Market cap ₩1.07TAs of Jul 21, 2026 close · updated once daily
A
Grade A65.9 ptsTop 20% of 2,523 stocks
Financial strength
54.4
Growth momentum
71.4
Price attractiveness
75.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

54.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
57.9%
✗ Below median · Top 55.5% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
82.1%
✗ Below median · Top 82.3% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
10.4%
✓ Above median · Top 18.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
5.7%
✓ Above median · Top 26.2% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

71.4
How much did revenue grow in a year?
Revenue growth (YoY)
18.5%
✓ Above median · Top 25.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
7.9%
✓ Above median · Top 40.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
25.7%
✓ Above median · Top 33.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
111.1%
✓ Above median · Top 15.3% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

75.2
Is the price expensive relative to earnings?
P/E (price-to-earnings)
14.1x
✓ Above median · Top 20.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.81x
✓ Above median · Top 28.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15